Michael C. Jensen
0000-0001-9084-1361
Publication & Citation Trends
Publications
0 total
STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors
Cited by 26
Semantic Scholar
DIPG-11. PRECLINICAL EFFICACY OF B7-H3 CAR T CELLS IN COMBINATION WITH ONC206 OA
Cited by 0
Semantic Scholar
Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing OA
Cited by 31
Semantic Scholar
TRLS-01. INTRAVENTRICULAR B7-H3 CAR T CELLS FOR DIFFUSE INTRINSIC PONTINE GLIOMA: SAFETY AND EFFICACY REPORT FROM THE COMPLETED PHASE 1 TRIAL BRAINCHILD-03 OA
Cited by 2
Semantic Scholar
IMMU-01. PIONEERING QUAD-TARGETING CAR T CELL THERAPY IN PEDIATRIC CNS TUMORS – ANALYSIS FROM THE INITIAL PATIENTS TREATED ON THE FIRST-IN-HUMAN PHASE 1 TRIAL BRAINCHILD-04 OA
Cited by 3
Semantic Scholar
Locoregional CAR T Cells for the Treatment of CNS Tumors in Children: Investigational Drug Service Pharmacy Activities.
Cited by 3
Semantic Scholar
Feasibility and favorable responses after investigational CAR T-cell therapy for relapsed and refractory infant ALL OA
Cited by 7
Semantic Scholar
Abstract LB121: BrainChild-03: Intraventricular B7-H3 CAR T cells for recurrent/refractory central nervous system tumors and non-pontine diffuse midline glioma in children and young adults
Cited by 0
Semantic Scholar
Research Topics
Corporate Finance and Governance
(89)
Financial Markets and Investment Strategies
(37)
Auditing, Earnings Management, Governance
(34)
Financial Reporting and Valuation Research
(34)
Banking stability, regulation, efficiency
(22)
Affiliations
University of Southern California
American Bar Association
National Bureau of Economic Research
Harvard University
Johns Hopkins University